JP6427104B2 - Ｔａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤 - Google Patents

Ｔａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤 Download PDF

Info

Publication number
JP6427104B2
JP6427104B2 JP2015545156A JP2015545156A JP6427104B2 JP 6427104 B2 JP6427104 B2 JP 6427104B2 JP 2015545156 A JP2015545156 A JP 2015545156A JP 2015545156 A JP2015545156 A JP 2015545156A JP 6427104 B2 JP6427104 B2 JP 6427104B2
Authority
JP
Japan
Prior art keywords
concentration
formulation
tat
trehalose
histidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015545156A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016502537A5 (enExample
JP2016502537A (ja
Inventor
ジョナサン デイヴィッド ガーマン，
ジョナサン デイヴィッド ガーマン，
Original Assignee
ノノ インコーポレイテッド
ノノ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノノ インコーポレイテッド, ノノ インコーポレイテッド filed Critical ノノ インコーポレイテッド
Publication of JP2016502537A publication Critical patent/JP2016502537A/ja
Publication of JP2016502537A5 publication Critical patent/JP2016502537A5/ja
Application granted granted Critical
Publication of JP6427104B2 publication Critical patent/JP6427104B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015545156A 2012-11-28 2013-11-25 Ｔａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤 Expired - Fee Related JP6427104B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261730952P 2012-11-28 2012-11-28
US61/730,952 2012-11-28
PCT/US2013/071755 WO2014085349A1 (en) 2012-11-28 2013-11-25 Lyophilized formulation of tat-nr2b9c

Publications (3)

Publication Number Publication Date
JP2016502537A JP2016502537A (ja) 2016-01-28
JP2016502537A5 JP2016502537A5 (enExample) 2016-12-22
JP6427104B2 true JP6427104B2 (ja) 2018-11-21

Family

ID=50828392

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015545156A Expired - Fee Related JP6427104B2 (ja) 2012-11-28 2013-11-25 Ｔａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤

Country Status (18)

Country Link
US (1) US20140162957A1 (enExample)
EP (1) EP2925338B8 (enExample)
JP (1) JP6427104B2 (enExample)
KR (1) KR102166374B1 (enExample)
CN (2) CN105101986B (enExample)
AU (1) AU2013352437B2 (enExample)
CA (1) CA2892965C (enExample)
DK (1) DK2925338T3 (enExample)
ES (1) ES2725598T3 (enExample)
HR (1) HRP20190707T1 (enExample)
HU (1) HUE043820T2 (enExample)
LT (1) LT2925338T (enExample)
MX (1) MX365325B (enExample)
PL (1) PL2925338T3 (enExample)
PT (1) PT2925338T (enExample)
SI (1) SI2925338T1 (enExample)
TR (1) TR201905787T4 (enExample)
WO (1) WO2014085349A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
KR102605540B1 (ko) 2014-05-28 2023-11-22 노노 인코포레이티드 Tat-nr2b9c의 클로라이드 염
US10206878B2 (en) 2014-05-28 2019-02-19 Nono Inc. Lyophilized formulation of TAT-NR2B9C with acetylation scavenger
EP3247400A1 (en) * 2015-01-18 2017-11-29 Biogen MA Inc. Formulations and screening of biological therapeutic agents
KR20180135493A (ko) * 2016-04-27 2018-12-20 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경독성 관련 손상의 치료 방법
CN106619170A (zh) * 2016-10-26 2017-05-10 暨南大学 包含stp和生长因子的活性组合物及其化妆品或护肤品
CN110627877A (zh) * 2019-09-25 2019-12-31 成都奥达生物科技有限公司 一种psd-95抑制剂
CN115279797A (zh) * 2020-01-09 2022-11-01 诺诺公司 用于治疗中风和相关疾病的抗纤溶酶肽

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605884A (en) * 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
US7858322B2 (en) * 2003-12-23 2010-12-28 Nono, Inc. Method of determining inhibition of binding to TRPM7 protein
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
WO2007002395A1 (en) * 2005-06-23 2007-01-04 Arbor Vita Corporation Methods and compositions for modulating cox
US8633160B2 (en) * 2005-12-30 2014-01-21 Nono Inc. Small molecule inhibitors of PDZ interactions
SG171670A1 (en) * 2006-05-05 2011-06-29 Transtech Pharma Inc Rage fusion proteins, formulations, and methods of use thereof
EP1884521A1 (en) 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
AU2009288088B2 (en) * 2008-09-03 2014-12-04 Nono Inc. Agents and methods for treatment of pain
US8099602B2 (en) * 2008-09-26 2012-01-17 Mykonos Software, Inc. Methods for integrating security in network communications and systems thereof
BRPI1010718A2 (pt) * 2009-06-10 2016-03-15 Nono Inc sistemas modelo e regimes de tratamento para tratar doença neurológica.
AU2010259986B2 (en) * 2009-06-10 2015-04-02 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
EP2616094B1 (en) * 2010-08-12 2017-11-08 NoNO Inc. Treatment of penetrative injury to the brain

Also Published As

Publication number Publication date
CA2892965C (en) 2021-06-01
PL2925338T3 (pl) 2019-11-29
AU2013352437B2 (en) 2018-04-12
AU2013352437A1 (en) 2015-07-09
KR20150094656A (ko) 2015-08-19
LT2925338T (lt) 2019-05-10
MX2015006784A (es) 2015-10-29
US20140162957A1 (en) 2014-06-12
PT2925338T (pt) 2019-05-31
SI2925338T1 (sl) 2019-09-30
CN105101986B (zh) 2018-09-25
EP2925338A4 (en) 2016-05-25
WO2014085349A1 (en) 2014-06-05
EP2925338B8 (en) 2019-05-22
TR201905787T4 (tr) 2019-05-21
EP2925338B1 (en) 2019-03-27
HRP20190707T1 (hr) 2019-10-04
HUE043820T2 (hu) 2019-09-30
HK1215793A1 (en) 2016-09-15
BR112015012422A2 (pt) 2017-09-12
EP2925338A1 (en) 2015-10-07
KR102166374B1 (ko) 2020-10-15
ES2725598T3 (es) 2019-09-25
MX365325B (es) 2019-05-29
CN109106941A (zh) 2019-01-01
CA2892965A1 (en) 2014-06-05
DK2925338T3 (da) 2019-05-06
CN105101986A (zh) 2015-11-25
JP2016502537A (ja) 2016-01-28

Similar Documents

Publication Publication Date Title
US11911438B2 (en) Chloride salt of TAT-NR2B9C
JP6427104B2 (ja) Ｔａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤
US10912817B2 (en) Prelyophilized, lyophilized and reconstituted formulations comprising TAT-NR2B9C with d-amino acids, histidine and trehalose
US20220096383A1 (en) Lyophilized formulation of tat-nr2b9c with acetylation scavenger
HK40044216A (en) Chloride salt of tat-nr2b9c
HK1215793B (en) Lyophilized formulation of tat-nr2b9c
HK1236205A1 (en) Chloride salt of tat-nr2b9c
HK1236205B (en) Chloride salt of tat-nr2b9c

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180608

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181009

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181026

R150 Certificate of patent or registration of utility model

Ref document number: 6427104

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees